DXCM Dexcom
Durable CGM duopolist with a long Type 2 runway, but pricing pressure caps margins; fairly-to-richly priced.
The story
Dexcom is one of two scaled players in continuous glucose monitoring, sharing a duopoly with Abbott's Libre. Its moat comes from sensor accuracy, integration with insulin pumps, clinician loyalty and reimbursement relationships. It is a maturing growth company: the intensive-insulin market is well penetrated, and the remaining runway is Type 2 non-insulin users, international markets and over-the-counter products like Stelo. Growth in those segments comes with lower prices as more sales move to the pharmacy channel and Abbott competes on cost.
First-year growth of 13% is below the 17% five-year CAGR, reflecting a larger revenue base and pricing pressure in Type 2 and OTC. Margins move from 26% to a sustainable 27%, because scale gains are offset by price cuts, so I do not assume medtech-peak margins. Sales-to-capital of 1.6 (TTM is 1.25) reflects manufacturing scale-up already being in place. The 10-year horizon fits a durable duopoly with a long Type 2 runway, but not a 15-year franchise given Abbott's cost advantage.
Value drivers
| Revenue growth (Y1) | 13.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 27.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.60 |
| Beta | 1.05 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.7% |
| Terminal WACC | 9.5% |
Valuation bridge
| PV of explicit FCFF | 7.91B |
| PV of terminal value | 12.08B |
| Equity value | 19.28B |
| ÷ shares → per share | $51.08 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 5.62B | 13.0% | 26.2% | 1.13B | 403.75M | 728.76M | 664.42M |
| 2 | 6.29B | 11.9% | 26.4% | 1.28B | 419.19M | 857.67M | 712.91M |
| 3 | 6.97B | 10.9% | 26.6% | 1.43B | 427.79M | 998.16M | 756.45M |
| 4 | 7.66B | 9.8% | 26.8% | 1.58B | 428.39M | 1.15B | 793.77M |
| 5 | 8.33B | 8.8% | 27.0% | 1.73B | 420.00M | 1.31B | 823.76M |
| 6 | 8.97B | 7.7% | 27.0% | 1.86B | 401.93M | 1.46B | 838.03M |
| 7 | 9.57B | 6.7% | 27.0% | 1.99B | 373.79M | 1.61B | 843.75M |
| 8 | 10.11B | 5.6% | 27.0% | 2.10B | 335.58M | 1.76B | 840.68M |
| 9 | 10.57B | 4.6% | 27.0% | 2.19B | 287.74M | 1.90B | 828.85M |
| 10 | 10.94B | 3.5% | 27.0% | 2.27B | 231.14M | 2.04B | 808.58M |
Key risks
- Abbott Libre's lower prices compress pricing, especially in the pharmacy and Type 2 non-insulin channels
- Weaker reimbursement or slow coverage for Type 2 non-insulin patients limits the volume runway
- Quality and recall problems or FDA warning letters that hurt sensor reliability and trust
- GLP-1 drugs reduce disease progression and slow growth in insulin-using patients
Catalysts
- Broader reimbursement for Type 2 non-insulin CGM and scaling of the Stelo OTC product
- Next-generation sensor launches (longer wear, smaller form factor) that improve unit economics and gross margin